BC Innovations | Jan 17, 2018
Distillery Therapeutics


INDICATION: Liver cancer; ovarian cancer; sarcoma Patient sample and mouse studies suggest inhibiting GADD45B could help treat hepatocellular cancer (HCC), ovarian cancer and fibrosarcoma. In HCC and ovarian cancer patients, high tumor levels of GADD45B...
BC Extra | Dec 3, 2015
Financial News

Kesios' series A brings L19M

Kesios Therapeutics Ltd. (London, U.K.) closed a L19 million ($28.5 million) series A round led by existing investor Imperial Innovations Group plc (LSE:IVO). New investors SV Life Sciences and Abingworth also participated. Chairman and newly...
BC Innovations | Nov 6, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Growth arrest and DNA-damage-inducible 45b (GADD45B); mitogen-activated protein kinase kinase 7 (MAP2K7; MKK7) Studies in patient samples and mice suggest inhibiting the...
BioCentury | Oct 20, 2014
Emerging Company Profile

Kesios: Reactivating apoptosis

Kesios Therapeutics Ltd. is targeting a downstream component of the NF-kappa B signaling pathway that is overexpressed in multiple myeloma cells with the aim of providing efficacy similar to other MM therapies, but with a...
Items per page:
1 - 4 of 4